Design Therapeutics reports Q3 2021 net loss $11.3M; FA program on track for H1 2022

Design Therapeutics, Inc.

2022-Q3 EPS reported -$0.57

Net loss $11.3M for Q3 2021; R&D expenses $8.5M, G&A $2.8M.
Cash, cash equivalents and securities total $393.7M as of Sept 30, 2021.
FA GeneTAC candidate on track for Phase 1 initiation in H1 2022; topline data expected in 2022.
DM1 program: preclinical data show near-complete resolution of foci; clinical start planned for 2023.
Company to present at Piper Healthcare Conference Nov 30 – Dec 2, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.